Who we are
Axxam is a privately owned innovative Partner Research Organization (iPRO) providing, since its inception in 2001, excellent quality services in the early phases of drug discovery, including assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural) or those provided by our clients, hit identification and hit validation. Our clients are distributed around the globe and active in the Life Sciences as pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages.
Our passion for conducting clients’ discovery programs is complemented by the pharmaceutical industry experience from both, the management as well as the scientist teams. Each customer is equally important to us and this has been recognized by more than 70% of our business being based on repeated contracts.
We are guided by a truly collaborative mentality, based on transparent processes and open communication. We are providing resources, expertise in a broad range of target classes, know-how, but also a problem-solving attitude and passion for our work.
Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures.
Where we are
The headquarters of Axxam S.p.A. are located at OpenZone Campus in Bresso, a small city in the outskirt of Milan (Italy) that hosts also our biology laboratories while our medicinal chemistry laboratories are located at the Novartis Torre Campus in Torre Annunziata (Naples, Italy).
Axxam Group has two screening facilities, one located at the headquarters in Italy and one in Constance (Germany), under Axxam GmbH, a subsidiary of Axxam S.p.A. that counts also a second business unit, called IMAX Discovery, focused on offering services to food and beverages, fragrance and cosmetic industries.
Finally, our business development offices and collaborators are spread across Europe, US and Japan.